nach oben

American Journal of Clinical Dermatology

Erschienen in:

04.08.2021 | Therapy in Practice

A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris

verfasst von: Katerina Svigos, Lu Yin, Lauren Fried, Kristen Lo Sicco, Jerry Shapiro

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Lichen planopilaris is a primary lymphocytic cicatricial alopecia that commonly presents with hair loss at the vertex or parietal scalp. Patients may also have associated scalp itching, burning or tenderness. Due to scarring, hair loss is typically permanent. The main goals of treatment are reducing symptoms and preventing disease progression and further hair loss. Currently, the literature has limited evidence on treatments for this difficult condition, and most available evidence is from case reports and case series. Furthermore, the evidence shows a varied response to therapy, with frequent reports of poor response. This article reviews the diagnosis of this rare disease, summarize the currently available treatments, and provide insights and practices from alopecia experts.

Babahosseini H, Tavakolpour S, Mahmoudi H, Balighi K, Teimourpour A, Ghodsi SZ, et al. Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients. J Dermatol Treat. 2019;30(6):598–604. https://doi.org/10.1080/09546634.2018.1542480.CrossRef

Kang H, Alzolibani AA, Otberg N, Shapiro J. Lichen planopilaris. Dermatol Ther. 2008;21(4):249–56. https://doi.org/10.1111/j.1529-8019.2008.00206.x.CrossRefPubMed

Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg. 2009;28(1):3–10. https://doi.org/10.1016/j.sder.2008.12.006.CrossRefPubMed

Errichetti E, Figini M, Croatto M, Stinco G. Therapeutic management of classic lichen planopilaris: a systematic review. Clin Cosmet Investig Dermatol. 2018;11:91–102. https://doi.org/10.2147/CCID.S137870.CrossRefPubMedPubMedCentral

Trager MH, Lavian J, Lee EY, Gary D, Jenkins F, Christiano AM, et al. Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York city health care system. J Am Acad Dermatol. 2021;84(4):1166–9. https://doi.org/10.1016/j.jaad.2020.10.081.CrossRefPubMed

Ochoa BE, King LE Jr, Price VH. Lichen planopilaris: Annual incidence in four hair referral centers in the United States. J Am Acad Dermatol. 2008;58(2):352–3. https://doi.org/10.1016/j.jaad.2007.11.007.CrossRefPubMed

Lepe K, Nassereddin A, Salazar FJ. Lichen Planopilaris. Treasure Island: StatPearls Publishing; 2021.

Aldoori N, Dobson K, Holden CR, McDonagh AJ, Harries M, Messenger AG. Frontal fibrosing alopecia: possible association with leave-on facial skin care products and sunscreens; a questionnaire study. Br J Dermatol. 2016;175(4):762–7. https://doi.org/10.1111/bjd.14535.CrossRefPubMed

Lee JA, Levy DA, Patel KG, Brennan E, Oyer SL. Hair transplantation in frontal fibrosing alopecia and lichen planopilaris: a systematic review. Laryngoscope. 2021;131(1):59–66. https://doi.org/10.1002/lary.28551.CrossRefPubMed

10.

Chiang YZ, Tosti A, Chaudhry IH, Lyne L, Farjo B, Farjo N, et al. Lichen planopilaris following hair transplantation and face-lift surgery. Br J Dermatol. 2012;166(3):666–370. https://doi.org/10.1111/j.1365-2133.2011.10692.x.CrossRefPubMed

11.

Monselise A, Chan LJ, Shapiro J. Break dancing: a new risk factor for scarring hair loss. J Cutan Med Surg. 2011;15(3):177–9. https://doi.org/10.2310/7750.2011.10032.CrossRefPubMed

12.

Bolduc C, Sperling LC, Shapiro J. Primary cicatricial alopecia: lymphocytic primary cicatricial alopecias, including chronic cutaneous lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia, and Graham-Little syndrome. J Am Acad Dermatol. 2016;75(6):1081–99. https://doi.org/10.1016/j.jaad.2014.09.058.CrossRefPubMed

13.

Cevasco NC, Bergfeld WF, Remzi BK, de Knott HR. A case-series of 29 patients with lichen planopilaris: the Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol. 2007;57(1):47–53. https://doi.org/10.1016/j.jaad.2007.01.011.CrossRefPubMed

14.

Manatis-Lornell A, Okhovat JP, Marks DH, Hagigeorges D, Senna MM. Comorbidities in patients with lichen planopilaris: a retrospective case-control study. J Am Acad Dermatol. 2020;83(1):205–8. https://doi.org/10.1016/j.jaad.2019.07.018.CrossRefPubMed

15.

Larkin SC, Cantwell HM, Imhof RL, Torgerson RR, Tolkachjov SN. Lichen planopilaris in women: a retrospective review of 232 women seen at mayo clinic from 1992 to 2016. Mayo Clin Proc. 2020;95(8):1684–95. https://doi.org/10.1016/j.mayocp.2020.02.028.CrossRefPubMed

16.

Soares VC, Mulinari-Brenner F, Souza TE. Lichen planopilaris epidemiology: a retrospective study of 80 cases. An Bras Dermatol. 2015;90(5):666–70. https://doi.org/10.1590/abd1806-4841.20153923.CrossRefPubMedPubMedCentral

17.

Chiang C, Sah D, Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010;62(3):387–92. https://doi.org/10.1016/j.jaad.2009.08.054.CrossRefPubMed

18.

Crisóstomo MR, Crisóstomo MC, Crisóstomo MG, Gondim VJ, Crisóstomo MR, Benevides AN. Hair loss due to lichen planopilaris after hair transplantation: a report of two cases and a literature review. An Bras Dermatol. 2011;86(2):359–62. https://doi.org/10.1590/s0365-05962011000200024.CrossRefPubMed

19.

Morais KL, Martins CF, Anzai A, Valente NYS, Romiti R. Lichen planopilaris with pustules: a diagnostic challenge. Skin Appendage Disord. 2018;4(2):61–6. https://doi.org/10.1159/000478268.CrossRefPubMed

20.

Donovan J. Lichen planopilaris after hair transplantation: report of 17 cases. Dermatol Surg. 2012;38(12):1998–2004. https://doi.org/10.1111/dsu.12014.CrossRefPubMed

21.

Baquerizo Nole KL, Nusbaum B, Pinto GM, Miteva M. Lichen planopilaris in the androgenetic alopecia area: a pitfall for hair transplantation. Skin Appendage Disord. 2015;1(1):49–53. https://doi.org/10.1159/000381588.CrossRefPubMedPubMedCentral

22.

Lajevardi V, Mahmoudi H, Moghanlou S, Ansari M, Teimourpour A, Daneshpazhooh M. Assessing the correlation between trichoscopic features in lichen planopilaris and lichen planopilaris activity index. Australas J Dermatol. 2019;60(3):214–8. https://doi.org/10.1111/ajd.13022.CrossRefPubMed

23.

Nirmal B, George R, Kodiatte TA. Invisible lichen planopilaris unmasked by dermatoscopy. Int J Trichol. 2017;9(2):76–8. https://doi.org/10.4103/ijt.ijt_81_16.CrossRef

24.

Jain N, Doshi B, Khopkar U. Trichoscopy in alopecias: diagnosis simplified. Int J Trichol. 2013;5(4):170–8. https://doi.org/10.4103/0974-7753.130385.CrossRef

25.

Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1–12. https://doi.org/10.1016/j.jaad.2017.04.1141.CrossRefPubMed

26.

Callender VD, Lawson CN, Onwudiwe OC. Hair transplantation in the surgical treatment of central centrifugal cicatricial alopecia. Dermatol Surg. 2014;40(10):1125–31. https://doi.org/10.1097/dss.0000000000000127.CrossRefPubMed

27.

Karadağ AS, Parish LC. Sarcoidosis: a great imitator. Clin Dermatol. 2019;37(3):240–54. https://doi.org/10.1016/j.clindermatol.2019.01.005.CrossRefPubMed

28.

Katta R, Nelson B, Chen D, Roenigk H. Sarcoidosis of the scalp: a case series and review of the literature. J Am Acad Dermatol. 2000;42(4):690–2.CrossRef

29.

Fernandez-Faith E, McDonnell J. Cutaneous sarcoidosis: differential diagnosis. Clin Dermatol. 2007;25(3):276–87. https://doi.org/10.1016/j.clindermatol.2007.03.004.CrossRefPubMed

30.

Prohaska J, Demaree E, Powers J, Cook C. Scalp sarcoidosis presenting as cicatricial alopecia. J Am Osteopath Assoc. 2018;118(12):824–6. https://doi.org/10.7556/jaoa.2018.175.CrossRefPubMed

31.

Knight L, Ngwanya M. Sarcoidosis of the scalp: the largest single-institutional case series. Int J Dermatol. 2019;58(8):e149–51. https://doi.org/10.1111/ijd.14483.CrossRefPubMed

32.

Kreutzer KM, Effendy I. Cicatricial alopecia related to folliculotropic mycosis fungoides. Dermatol Ther (Heidelb). 2020;10(5):1175–80. https://doi.org/10.1007/s13555-020-00429-0.CrossRefPubMedPubMedCentral

33.

Bi MY, Curry JL, Christiano AM, Hordinsky MK, Norris DA, Price VH, et al. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 2011;64(1):53–63. https://doi.org/10.1016/j.jaad.2009.12.056.CrossRefPubMed

34.

Nasimi M, Ahangari N, Lajevardi V, Mahmoudi H, Ghodsi SZ, Etesami I. Quality of life and mental health status in patients with lichen planopilaris based on Dermatology Life Quality Index and General Health Questionnaire-28 questionnaires. Int J Womens Dermatol. 2020;6(5):399–403. https://doi.org/10.1016/j.ijwd.2020.09.005.CrossRefPubMedPubMedCentral

35.

Alirezaei P, Ahmadpanah M, Rezanejad A, Soltanian A, Sadeghi Bahmani D, Brand S. Compared to controls, individuals with lichen planopilaris have more depression, a lower self-esteem, and a lower quality of life. Neuropsychobiology. 2019;78(2):95–103. https://doi.org/10.1159/000499135.CrossRefPubMed

36.

Kerkemeyer KL, Green J. Lichen planopilaris: a retrospective study of 32 cases in an Australian tertiary referral hair clinic. Australas J Dermatol. 2018;59(4):297–301. https://doi.org/10.1111/ajd.12772.CrossRefPubMed

37.

Vano-Galvan S, Trindadedearvalho L, Saceda-Corralo D, Rodrigues-Barata R, Kerkemeyer KL, Sinclair RD, et al. Oral minoxidil improves background hair thickness in lichen planopilaris. J Am Acad Dermatol. 2021;84(6):1684–6. https://doi.org/10.1016/j.jaad.2020.04.026.CrossRefPubMed

38.

Bergfeld W, Washenik K, Callender V, Zhang P, Quiza C, Doshi U, et al. A phase III, multicenter, parallel-design clinical trial to compare the efficacy and safety of 5% minoxidil foam versus vehicle in women with female pattern hair loss. J Drugs Dermatol. 2016;15(7):874–81.PubMed

39.

Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–85. https://doi.org/10.1067/mjd.2002.124088.CrossRefPubMed

40.

Abraham A, Roga G. Topical steroid-damaged skin. Indian J Dermatol. 2014;59(5):456–9. https://doi.org/10.4103/0019-5154.139872.CrossRefPubMedPubMedCentral

41.

Lyakhovitsky A, Amichai B, Sizopoulou C, Barzilai A. A case series of 46 patients with lichen planopilaris: demographics, clinical evaluation, and treatment experience. J Dermatol Treat. 2015;26(3):275–9. https://doi.org/10.3109/09546634.2014.933165.CrossRef

42.

Mehregan DA, Van Hale HM, Muller SA. Lichen planopilaris: clinical and pathologic study of forty-five patients. J Am Acad Dermatol. 1992;27(6 Pt 1):935–42. https://doi.org/10.1016/0190-9622(92)70290-v.CrossRefPubMed

43.

Akiyama M, Smith LT, Holbrook KA. Growth factor and growth factor receptor localization in the hair follicle bulge and associated tissue in human fetus. J Invest Dermatol. 1996;106(3):391–6. https://doi.org/10.1111/1523-1747.ep12343381.CrossRefPubMed

44.

Cervelli V, Garcovich S, Bielli A, Cervelli G, Curcio BC, Scioli MG, et al. The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: clinical and histomorphometric evaluation. Biomed Res Int. 2014;2014:760709. https://doi.org/10.1155/2014/760709.CrossRefPubMedPubMedCentral

45.

Yin L, Svigos K, Lo Sicco K, Shapiro J. Platelet-rich plasma. In: Alves R, Grimalt R, editors. Techniques in the evaluation and management of hair diseases. Boca Raton: CRC Press; 2021.

46.

Bolanca Z, Goren A, Getaldic-Svarc B, Vucic M, Situm M. Platelet-rich plasma as a novel treatment for lichen planopillaris. Dermatol Ther. 2016;29(4):233–5. https://doi.org/10.1111/dth.12343.CrossRefPubMed

47.

Dina Y, Aguh C. Use of platelet-rich plasma in cicatricial alopecia. Dermatol Surg. 2019;45(7):979–81. https://doi.org/10.1097/DSS.0000000000001635.CrossRefPubMed

48.

Jha AK. Platelet-rich plasma for the treatment of lichen planopilaris. J Am Acad Dermatol. 2018;79(5):e95–6. https://doi.org/10.1016/j.jaad.2018.05.029.CrossRefPubMed

49.

Özcan D, Tunçer Vural A, Özen Ö. Platelet-rich plasma for treatment resistant frontal fibrosing alopecia: a case report. Dermatol Ther. 2019;32(5):e13072. https://doi.org/10.1111/dth.13072.CrossRefPubMed

50.

Svigos K, Yin L, Shaw K, Gutierrez D, Peterson E, Lo Sicco K, et al. Use of platelet-rich plasma in lichen planopilaris and its variants: a retrospective case series demonstrating treatment tolerability without koebnerization. J Am Acad Dermatol. 2020;83(5):1506–9. https://doi.org/10.1016/j.jaad.2020.06.026.CrossRefPubMed

51.

Nichonncha E, Foley CC, Markham T. The role of hydroxychloroquine in the treatment of lichen planopilaris: a retrospective case series and review. Dermatol Ther. 2017. https://doi.org/10.1111/dth.12463.CrossRef

52.

Naeini FF, Saber M, Asilian A, Hosseini SM. Clinical efficacy and safety of methotrexate versus hydroxychloroquine in preventing lichen planopilaris progress: a randomized clinical trial. Int J Prev Med. 2017;8:37. https://doi.org/10.4103/ijpvm.IJPVM_156_17.CrossRefPubMedPubMedCentral

53.

Geamănu Pancă A, Popa-Cherecheanu A, Marinescu B, Geamănu CD, Voinea LM. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review. J Med Life. 2014;7(3):322–6.PubMedPubMedCentral

54.

Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–94. https://doi.org/10.1016/j.ophtha.2016.01.058.CrossRefPubMed

55.

Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–60. https://doi.org/10.1001/jamaophthalmol.2014.3459.CrossRefPubMed

56.

Henehan M, Montuno M, De Benedetto A. Doxycycline as an anti-inflammatory agent: updates in dermatology. J Eur Acad Dermatol Venereol. 2017;31(11):1800–8. https://doi.org/10.1111/jdv.14345.CrossRefPubMed

57.

Patel RS, Parmar M. Doxycycline hyclate. Treasure Island: StatPearls Publishing; 2021.

58.

Spring P, Spanou Z, de Viragh PA. Lichen planopilaris treated by the peroxisome proliferator activated receptor-γ agonist pioglitazone: lack of lasting improvement or cure in the majority of patients. J Am Acad Dermatol. 2013;69(5):830–2. https://doi.org/10.1016/j.jaad.2013.04.066.CrossRefPubMed

59.

Mardones F, Shapiro J. Lichen planopilaris in a Latin American (Chilean) population: demographics, clinical profile and treatment experience. Clin Exp Dermatol. 2017;42(7):755–9. https://doi.org/10.1111/ced.13203.CrossRefPubMed

60.

Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Dev Ther. 2020;14:951–9. https://doi.org/10.2147/dddt.S240615.CrossRef

61.

Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-41.e5. https://doi.org/10.1016/j.jaad.2017.02.054.CrossRefPubMed

62.

Zito PM, Bistas KG, Syed K. Finasteride. Treasure Island: StatPearls Publishing; 2021.

63.

Oliveira-Soares R, André MC, Peres-Correia M. Adverse effects with finasteride 5 mg/day for patterned hair loss in premenopausal women. Int J Trichol. 2018;10(1):48–50. https://doi.org/10.4103/ijt.ijt_73_15.CrossRef

64.

Mirmirani P, Karnik P. Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Arch Dermatol. 2009;145(12):1363–6. https://doi.org/10.1001/archdermatol.2009.283.CrossRefPubMedPubMedCentral

65.

George SJ, Hsu S. Lichen planopilaris treated with thalidomide. J Am Acad Dermatol. 2001;45(6):965–6. https://doi.org/10.1067/mjd.2001.119559.CrossRefPubMed

66.

Hodgens A, Sharman T. Corticosteroids. Treasure Island: StatPearls Publishing; 2021.

67.

Peterson EL, Gutierrez D, Brinster NK, Lo Sicco KI, Shapiro J. Response of lichen planopilaris to pioglitazone hydrochloride. J Drugs Dermatol. 2019;18(12):1276–9.PubMed

68.

Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol. 2009;129(5):1243–57. https://doi.org/10.1038/jid.2008.369.CrossRefPubMed

69.

Spring P, Spanou Z, de Viragh PA. Lichen planopilaris treated by the peroxisome proliferator activated receptor-gamma agonist pioglitazone: lack of lasting improvement or cure in the majority of patients. J Am Acad Dermatol. 2013;69(5):830–2. https://doi.org/10.1016/j.jaad.2013.04.066.CrossRefPubMed

70.

Lee B, Elston DM. The uses of naltrexone in dermatologic conditions. J Am Acad Dermatol. 2019;80(6):1746–52. https://doi.org/10.1016/j.jaad.2018.12.031.CrossRefPubMed

71.

Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Novel treatment using low-dose naltrexone for lichen planopilaris. J Drugs Dermatol. 2017;16(11):1140–2.PubMed

72.

Lajevardi V, Salarvand F, Ghiasi M, Nasimi M, Taraz M. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial. J Dermatol Treat. 2020. https://doi.org/10.1080/09546634.2020.1774488 (Epub 8 Jun 2020).CrossRef

73.

Pile HD, Sadiq NM. Isotretinoin. Treasure Island: StatPearls Publishing; 2021.

74.

Spano F, Donovan JC. Efficacy of oral retinoids in treatment-resistant lichen planopilaris. J Am Acad Dermatol. 2014;71(5):1016–8. https://doi.org/10.1016/j.jaad.2014.06.013.CrossRefPubMed

75.

Fatemi F, Mohaghegh F, Danesh F, Saber M, Rajabi P. Isotretinoin for the treatment of facial lichen planopilaris: a new indication for an old drug, a case series study. Clin Case Rep. 2020;8(12):2524–9. https://doi.org/10.1002/ccr3.3210.CrossRefPubMedPubMedCentral

76.

Mostafa N, Phan K, Smith S. Mycophenolate mofetil and lichen planopilaris: systematic review and meta-analysis. J Dermatol Treat. 2020. https://doi.org/10.1080/09546634.2020.1755416 (Epub 23 Apr 2020).CrossRef

77.

CellCept [package insert]. Roche Laboratories Inc; 2000.

78.

Hannoodee M, Mittal M. Methotrexate. Treasure Island: StatPearls Publishing; 2021.

79.

Bulbul Baskan E, Yazici S. Treatment of lichen planopilaris: methotrexate or cyclosporine a therapy? Cutan Ocul Toxicol. 2018;37(2):196–9. https://doi.org/10.1080/15569527.2017.1382503.CrossRefPubMed

80.

Fatemi Naeini F, Mohaghegh F, Jelvan M, Asilian A, Saber M. Cyclosporine or methotrexate, which one is more promising in the treatment of lichen planopilaris? A comparative clinical trial. Int Immunopharmacol. 2020;86:106765. https://doi.org/10.1016/j.intimp.2020.106765.CrossRefPubMed

81.

Safarini OA, Patel J. Calcineurin inhibitors. Treasure Island: StatPearls Publishing; 2021.

82.

Mirmirani P, Willey A, Price VH. Short course of oral cyclosporine in lichen planopilaris. J Am Acad Dermatol. 2003;49(4):667–71. https://doi.org/10.1067/s0190-9622(03)00873-9.CrossRefPubMed

83.

Chieregato C, Zini A, Barba A, Magnanini M, Rosina P. Lichen planopilaris: report of 30 cases and review of the literature. Int J Dermatol. 2003;42(5):342–5. https://doi.org/10.1046/j.1365-4362.2003.01695.x.CrossRefPubMed

84.

Yang CC, Khanna T, Sallee B, Christiano AM, Bordone LA. Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther. 2018;31(6):12656. https://doi.org/10.1111/dth.12656.CrossRef

85.

Batra P, Sukhdeo K, Shapiro J. Hair loss in lichen planopilaris and frontal fibrosing alopecia: not always irreversible. Skin Appendage Disord. 2020;6(2):125–9. https://doi.org/10.1159/000505439.CrossRefPubMedPubMedCentral

86.

Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatol (Oxf). 2019;58(Suppl 1):i34–42. https://doi.org/10.1093/rheumatology/key287.CrossRef

87.

Phillips TG, Slomiany WP, Allison R. Hair loss: common causes and treatment. Am Fam Phys. 2017;96(6):371–8.

88.

Liu YS, Jee SH, Chan JL. Hair transplantation for the treatment of lichen planopilaris and frontal fibrosing alopecia: a report of two cases. Australas J Dermatol. 2018;59(2):e118–22. https://doi.org/10.1111/ajd.12682.CrossRefPubMed

89.

Dahdah MJ, Iorizzo M. The role of hair restoration surgery in primary cicatricial alopecia. Skin Appendage Disord. 2016;2(1–2):57–60. https://doi.org/10.1159/000448104.CrossRefPubMedPubMedCentral

90.

Unger W, Unger R, Wesley C. The surgical treatment of cicatricial alopecia. Dermatol Ther. 2008;21(4):295–311. https://doi.org/10.1111/j.1529-8019.2008.00211.x.CrossRefPubMed

91.

Jiménez F. Commentary: lichen planopilaris after hair transplantation. Dermatol Surg. 2012;38(12):2005. https://doi.org/10.1111/j.1524-4725.2012.02578.x.CrossRefPubMed

Titel: A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris
verfasst von: Katerina Svigos
Lu Yin
Lauren Fried
Kristen Lo Sicco
Jerry Shapiro
Publikationsdatum: 04.08.2021
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 5/2021
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-021-00630-7

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Primary Localized Cutaneous Amyloidosis of Keratinocyte Origin: An Update with Emphasis on Atypical Clinical Variants

Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?

Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment

Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study

Review of Perineural Invasion in Keratinocyte Carcinomas